<DOC>
	<DOC>NCT01310322</DOC>
	<brief_summary>A study in healthy subjects and mild asthmatics to investigate Pharmacokinetics of AZD5423 when administered in different ways.</brief_summary>
	<brief_title>A Study in Healthy Subjects and Mild Asthmatics to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Male healthy subjects and male asthma patients aged 18 to 45 years (inclusive) Have a body mass index (BMI) between 18 and 30 kg/m2 (inclusive and rounding allowed) and weight between 50 and 100 kg (inclusive) Be able to inhale from the SPIRA nebuliser and Ineb® according to the provided instructions Asthma patients should fulfil the following criteria: Prebronchodilator forced expiratory volume at 1 second (FEV1) ≥70% of predicted normal value Asthma diagnosis according to GINA guidelines with a history of episodic wheeze and shortness of breath History of any clinically significant disease or disorder Any clinically relevant abnormal findings Current smokers Asthma patients: Worsening of asthma or respiratory infection within 6 weeks before screening Asthma patients: Use of inhaled, nasal, oral, rectal or parenteral corticosteroids within 30 days before first administration of investigational product and during the study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Healthy male volunteers</keyword>
	<keyword>mild asthmatics</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Bioavailability and AUC</keyword>
	<keyword>Level of AZD5423 in your blood</keyword>
</DOC>